Temporal Trends in Pulmonary Embolism Mortality Associated with COVID-19 in the United States: A 5-Year Retrospective Analysis

Abstract

Coronavirus disease 2019 (COVID-19) has been strongly associated with thrombotic complications, particularly pulmonary embolism (PE). This study aims to analyze the real-world impact of COVID-19 on PE-related mortality in the United States over the first 5 years of the pandemic. We conducted a retrospective observational study using the CDC WONDER database, combining data on mortality from PE and COVID-19 using the 10th revision of the International Classification of Diseases (ICD-10) codes I26 (PE) and U07.1 (COVID-19). The analysis spanned from 2020 to 2024. We found a peak in COVID-19-associated PE deaths in 2021, with an estimated crude rate of 211 × 1,000 PE deaths. This rate progressively declined over the following years, being 141 × 1,000 in 2022, 44 × 1,000 in 2023, and 29 × 1,000 in 2024, respectively. The estimated crude rate for COVID-19-associated PE in the United States was 111 × 1,000 PE deaths throughout the 5-year period. The results of our study show that COVID-19 may have contributed to nearly one-tenth of all PE deaths throughout the first 5 years of the pandemic. Despite the gradual decline over the years since its peak in 2021, the still sustained mortality suggests ongoing thrombotic risks, especially impacting high-risk populations, emphasizing the need for continued vigilance and prevention of thrombotic complications in COVID-19 patients.

Keywords

mortality - COVID-19 - pulmonary embolism

Publication History

Article published online:
24 February 2025

• References

• 1 Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021; 96 (01) 203-217
• 2 Porres-Aguilar M, Mukherjee D, Lazo-Langner A. Thromboprophylaxis strategies for hospitalized patients with COVID-19. Chest 2022; 162 (01) e69-e70
• 3 Rodriguez JJ, Munoz OC, Porres-Aguilar M, Mukherjee D. Thromboembolic complications in severe COVID-19: current antithrombotic strategies and future perspectives. Cardiovasc Hematol Disord Drug Targets 2021; 21 (01) 23-29
• 4 Tan BK, Mainbourg S, Friggeri A. et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021; 76 (10) 970-979
• 5 Wada N, Li Y, Gagne S. et al. Incidence and severity of pulmonary embolism in COVID-19 infection: ancestral, alpha, delta, and omicron variants. Medicine (Baltimore) 2023; 102 (48) e36417
• 6 Lippi G, Mattiuzzi C. Analysis of real-world data pulmonary embolism as the underlying cause of death during the COVID-19 pandemic. Thromb Res 2024; 241: 109089
• 7 Zuin M, Barco S, Giannakoulas G. et al. Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J Thromb Thrombolysis 2023; 55 (03) 490-498
• 8 French G, Hulse M, Nguyen D. et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic - United States, July 2020-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (46) 1613-1616
• 9 Porres-Aguilar M, Tapson VF, Rivera-Lebron BN. et al. Impact and role of pulmonary embolism response teams in venous thromboembolism associated with COVID-19. J Investig Med 2021; 69 (06) 1153-1155
• 10 Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Provisional Mortality on CDC WONDER Online Database. Data are from the final Multiple Cause of Death Files, 2018–2022, and from provisional data for years 2023–2024, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed January 20, 2025 at http://wonder.cdc.gov/mcd-icd10-provisional.html
• 11 International Statistical Classification of Diseases and Related Health Problems 10th Revision. ICD-10 Version. Accessed January 20, 2025 at: https://icd.who.int/browse10/2019/en
• 12 Fluss G, Cranwell V, Rao A. et al. COVID-19 Delta variant resulting in multi system thromboembolic disease. Ann Vasc Surg Brief Rep Innov 2022; 2 (03) 100101
• 13 Vettori M, Carpenè G, Salvagno GL. et al. Effects of recombinant SARS-CoV-2 spike protein variants on platelet morphology and activation. Semin Thromb Hemost 2024; 50 (02) 275-283
• 14 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
• 15 Schulman S, Arnold DM, Bradbury CA. et al; International Society on Thrombosis and Haemostasis. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2024; 22 (06) 1779-1797
• 16 Porres-Aguilar M, Anaya-Ayala JE, Mukherjee D. Review of pulmonary embolism. JAMA 2023; 329 (07) 592
• 17 Rossi AP, Gottin L, Donadello K. et al. Obesity as a risk factor for unfavourable outcomes in critically ill patients affected by Covid 19. Nutr Metab Cardiovasc Dis 2021; 31 (03) 762-768
• 18 Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 2020; 130 (04) 304-309